The mobile app records auditory data during sleep and securely transfers it to the cloud. Credit: Gregory Pappas on Unsplash.

EnsoData has expanded its capabilities in sleep apnoea screening and diagnosis with the acquisition of diagnostic technology from Resonea.

This move aims to reduce the cost and improve the systematic screening of sleep apnea across broad patient populations, addressing a condition that is often underdiagnosed yet exacerbates serious health issues such as cardiovascular and neurodegenerative diseases, and metabolic disorders.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

EnsoData CEO Justin Mortara said: “This is another step toward simplifying access to sleep care, helping to get more patients with sleep disorders diagnosed and ultimately connected with therapy.

“As a leader in healthcare AI solutions, EnsoData’s device-agnostic approach using pulse oximeters (PPG) and now smartphones supports our strategy to deploy flexible solutions that can easily scale to address the unmet clinical needs for sleep testing in the US and globally.”

The acquired technology introduces acoustic flow and microphone data channels, which will be integrated into a US Food and Drug Administration (FDA)-cleared mobile application.

See Also:

This approach allows for the pre-screening of patients for sleep apnoea and enhances the home sleep testing diagnostic capabilities.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The mobile app records auditory data at the time of sleep, securely transfers it to the cloud and performs a breath-by-breath acoustic analysis to identify sleep apnoea events or other disorders.

Patients can use their existing smartphones to facilitate this mobile-first, data-driven pre-screening process without the need for medical hardware.

In a diagnostic setting, sleep physicians will now have access to these channels for conducting sleep studies at home.

By combining a pulse oximeter cleared by the FDA with the mobile-based microphone and acoustic flow, clinicians can deepen their analysis and reporting capabilities available in EnsoSleep PPG, achieving a broader scope of quality clinical data.

This new technology enables physicians to deliver more personalised sleep apnoea diagnoses and tailor patient experiences when initiating treatment.

EnsoData expects the initial commercial availability of these new capabilities in the US within this year.

The companies have not disclosed the financial terms of the deal.